Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Improved survival in patients with multiple myeloma over time: A retrospective single-center study focusing on patients aged 80 years and above

View Full Paper
Ask AI
Bookmark
Share

Authors

MIMasaki IinoTMTakahiro MikawaMYMasanori Yoshikawa

Discussion

Loading...

Member takes

Overview

Retrospective analysis found that novel agents improved overall survival in elderly patients with multiple myeloma, suggesting the need for tailored treatments addressing comorbidities.

Key Points

  • Overall survival in elderly patients with multiple myeloma improved, with a significant increase in the 2-year survival rate.
  • The analysis showed a decline in cumulative mortality due to myeloma progression from 34.4% to 13.8% for patients 80 and older.
  • This observational study used methods like the log-rank test and the Kaplan–Meier method to evaluate survival outcomes.
  • Improved therapy with agents like daratumumab and pomalidomide highlights the need to address comorbidities in elderly patients.

Cite This Study

Iino et al. (2025) studied this question.

synapsesocial.com/papers/69362f4b4fa91c937236d7behttps://doi.org/10.1182/blood-2025-2203
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Main biologic and clinic features at presentation and treatment results in very elderly patients (> 75 Years) with  Multiple myeloma: A multicentric experience2025
  2. 2Chronological age predicts suboptimal multiple myeloma treatment independent of frailty and socioenvironmental factors: A retrospective multi-center cohort study2025
  3. 3Temporal trends in treatment patterns and overall survival for multiple myeloma management in Taiwan using the national health insurance claims database2025
  4. 4Survival differences in transplant ineligible multiple myeloma patients in Japan and Taiwan: Exploring the potential influence of timely and unrestricted access to novel therapies2025 · 1 citations
  5. 5Trends in mortality from multiple myeloma in patients younger than 55 years of age in the United States: A retrospective analysis from 1999 to 20202025